22 results about "Synovial tissue" patented technology

The invention belongs to the technical field of biomedicine, and particularly relates to application of DHX58 as a diagnostic marker and a therapeutic target of rheumatoid arthritis. Experiments prove that the DXH58 level in rheumatoid arthritis involved parts such as serum and synovial tissues of rheumatoid arthritis patients is remarkably increased, DHX58 and rheumatoid arthritis are positively correlated, and the DHX58 gene or DHX58 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of rheumatoid arthritis. Experiments prove that the targeted DHX58 can be used as an effective way for treating rheumatoid arthritis. The application has important meanings for researching the effect of DHX58 in rheumatoid arthritis, understanding the mechanism of RA disease and developing a new treatment strategy.

The invention relates to application of a miR-155-5p inhibitor delivered by an exosome of a targeted synovitis macrophage to treatment of osteoarthritis, and belongs to the technical field of biological medicines. According to the scheme, the exosome drug delivery system for targeting the synovial inflammatory macrophages in the osteoarthritis, which contains the miR-155-5p inhibitor, is prepared through a genetic engineering technology, so that the exosome derived from stem cells is targeted to inflammatory synovial tissues, and damaged cartilage tissues are repaired and inflammation is resisted based on the stem cell exosome; compared with the prior art, the application has the advantages that the combined action of inhibiting the osteoarthritis injury and inhibiting the miR-155-5p so as to resist synovitis is realized, the osteoarthritis injury repair can be better applicable, a new scheme for treating the osteoarthritis is provided, a support is provided for clinical transformation, and the application value is extremely high.

The invention belongs to the field of biological medicine, and discloses a chicoric acid (CA)-loaded tetrahedral framework nucleic acid (tFNA) nano preparation for treating acute gouty arthritis. According to the preparation, tFNA formed by self-assembly is taken as a carrier, and a natural active ingredient CA is loaded to form a CA-tFNA compound. The compound overcomes the defects that CA is poor in water solubility and low in bioavailability, and existing drugs are weak in targeting and large in side effect. Through the targeted delivery and synergistic effect of tFNA, the preparation can be effectively enriched in inflammatory joints, significantly inhibit NF-kappa B signal pathways, and down-regulate the expression of key proinflammatory factors such as TNF-alpha and IL-1beta, so that joint swelling and synovial tissue damage are relieved, and repair is promoted. Experiments show that the traditional Chinese medicine composition is remarkable in curative effect and good in safety, and a novel efficient treatment strategy is provided for acute gouty arthritis.

The invention belongs to the technical field of biomedicine, and particularly relates to WTAP as a clinical diagnosis marker for rheumatoid arthritis and application of the WTAP. Experiments prove that the WTAP level in rheumatoid arthritis involved parts such as serum and synovial tissues of rheumatoid arthritis patients is remarkably higher than that of normal people, the WTAP and the rheumatoid arthritis are positively correlated, and the WTAP gene or WTAP protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of the rheumatoid arthritis; the CIA mouse with the WTAP gene knocked out shows that the illness state is relieved, and the symptoms are relieved, so that the WTAP can be used as an effective target for treating rheumatoid arthritis.

The invention discloses an application of TRBC2 in diagnosis of gout. According to the application, a recognized moving meniscus tearing patient (equivalent to a completely healthy synovial tissue) without gout medical history is taken as a contrast, single cell transcriptome analysis is carried out on the basis of a clinical biological sample, and a marker TRBC2 of a T cell subset is found to have significant difference in gout patients; a Raman spectrum technology is further adopted to find that the TRBC2 protein is specifically and highly expressed in synovial tissues of gouty arthritis patients and has relatively high diagnosis efficiency, and the TRBC2 is relatively high in clinical value and wide in application prospect when being used as a marker for diagnosing gout.

The invention provides a muscle-bone injury area identification method and system, and relates to the technical field of muscle-bone image injury identification. The method comprises the following steps: acquiring a two-dimensional gray-scale ultrasonic image of a target muscle-bone injury area, and positioning a synovial tissue area from the two-dimensional gray-scale ultrasonic image; extracting target feature information from the synovial tissue region; and determining the inflammation activity degree of the synovial tissue according to the target feature information. According to the method, Doppler blood flow signals are completely bypassed, the rheumatism inflammation activity degree is evaluated only through rich information contained in the two-dimensional gray-scale ultrasonic image, and therefore interference of probe pressure artifacts is thoroughly avoided.

The application discloses application of TRBC2 in diagnosis of gout. In the application, patients with torn meniscus (equivalent to completely healthy synovial tissue) without a history of gout are used as a control, single-cell transcriptome analysis is carried out based on clinical biological samples, it is found that the marker TRBC2 of T cell subpopulation presents significant difference in gout patients, further Raman spectrum technology is used to find that TRBC2 protein is specifically highly expressed in synovial tissue of gouty arthritis patients, and has high diagnostic efficiency. The clinical value of TRBC2 as a marker for diagnosing gout is high, and the application prospect is wide.

The application discloses application of myrtenal in preparation of a medicine for preventing and / or treating rheumatoid arthritis. The application verifies for the first time that myrtenal can block the RA inflammatory cascade from multiple aspects, and overcomes the limitation that single-target treatment is easy to produce drug resistance. Specifically, myrtenal can reduce the levels of inflammatory factors and metal proteins; inhibit the proliferation, migration and invasion of synovial fibroblasts SFs; inhibit the expression of glycolysis-related genes, reduce sugar metabolites; inhibit the synovial tissue hyperplasia, inflammatory cell infiltration, bone erosion and bone destruction of mice joints; promote the mental state of arthritis mice to be obviously improved, the food intake to be increased, the hair to be shiny, the joint swelling to be subsided, the bruise of the ankle joint to be subsided, the skin to be improved, and the activity to be sensitive. Therefore, the application proposes a new medical use of myrtenal in treating rheumatoid arthritis, and develops a brand-new therapeutic indication of myrtenal.

The application provides a kind of cartilage polypeptide composition and its preparation method, the cartilage polypeptide 30-45%, auxiliary agent 10-25%, growth agent 3-8%, slow-release agent 2-9%, the balance is water, the application will cartilage polypeptide, auxiliary agent, growth agent and slow-release agent several ingredients scientific compatibility, preparation has the composition of protecting cartilage tissue, anti-inflammatory pain, effectively increase bone density effect, improve synovial tissue, there is no rebound ineffective condition after drug withdrawal.

This invention discloses the application of PT-129 in the preparation of drugs for treating rheumatoid arthritis (RA), belonging to the field of RA treatment. This invention is the first to demonstrate that the compound PT-129 can target and intervene in the synovial microenvironment, effectively inhibiting the abnormal activation behaviors of RA fibroblast-like synovial cells (FLS) such as proliferation, migration, and invasion, and downregulating the expression of N-cadherin and MMP3 proteins in synovial tissue. This invention provides a combined drug formulation containing PT-129 and RGFP966. This composition exhibits a significant synergistic effect in vivo, effectively relieving joint swelling, increasing bone density and trabecular bone thickness, reducing trabecular bone separation, thereby inhibiting cartilage degradation and bone destruction. This invention provides a novel targeted drug and combination therapy with definite efficacy for the clinical intervention of RA, possessing extremely high clinical application development value.

The utility model relates to the technical field of medical equipment, in particular to a shoulder arthroscopy sleeve with a drag hook function, which comprises a sleeve, a latch groove is arranged on the surface of the sleeve, an adjusting switch is fittingly mounted in the latch groove and comprises a position adjusting part and an angle adjusting part, and the position adjusting part is provided with a hook. The position adjusting part is used for controlling the angle adjusting part to linearly slide in the sleeve, two sets of drag hooks distributed symmetrically are rotationally connected to the angle adjusting part, and the angle adjusting part is used for controlling adjustment of the opening and closing angle between the two sets of drag hooks. According to the utility model, the draw hooks are arranged in the sleeve, and the movement, opening and closing of the draw hooks are controlled through the adjusting switch, so that when the sleeve is inserted into the shoulder joint of a patient, muscle tissues or synovial tissues in the sleeve can be expanded through unfolding of the two groups of draw hooks, and further, a shielding area in the sleeve is exposed; therefore, a clearer and more stable operation view is provided.

The application discloses a paeonol-loaded plant nanovesicle and application thereof in preparation of a medicine for regulating rheumatoid arthritis; the plant nanovesicle takes gardenia-derived exosome as a carrier, loads paeonol through an ultrasonic method, and is modified with a cyclic peptide RGD and a CD47 mimetic peptide on the surface, so that the plant nanovesicle can not only avoid being removed by macrophages, but also can penetrate a synovial vascular barrier and a dense extracellular matrix and be accurately delivered to an inflammatory synovial tissue, the delivery system effectively improves the stability and bioavailability of paeonol, can down-regulate a MALAT1 related signal path, inhibit abnormal activation of ERK / MAPK, and significantly reduce the expression of inflammatory factors such as IL-2, IL-6 and TNF-alpha, thereby relieving synovial inflammation of rheumatoid arthritis; the application has high targeting, long circulation, low immunogenicity and multi-dosage form adaptability, provides a novel delivery strategy of a safe and efficient active ingredient of traditional Chinese medicine, and has a wide application prospect.

The invention provides application of a composition in treatment of knee osteoarthritis. According to the invention, two rat knee osteoarthritis models (the former is called as an ACLT-induced KOA model for short, and the latter is called as a papain-induced KOA model for short) are established by respectively utilizing methods of combining anterior cruciate ligament transection (ACLT) with running and injecting papain composite L-cysteine into an articular cavity; the composition provided by the invention is used for treating two rat KOA models. Results show that the composition can improve knee joint swelling of two KOA rats, increase the pain threshold, improve the abnormal gait state, relieve cartilage injury, inhibit ACLT-induced abnormal change of a KOA rat knee joint subchondral bone microstructure and papain-induced PGE2 content in KOA rat synovial tissue, and can be used for preparing a medicine for treating osteoporosis. The level of inflammatory factors in serum and joint lavage fluid of the two KOA rats is reduced, and the discovery shows that the KOA has important application in treatment of knee osteoarthritis.

The application discloses a new application of m6A modified gene GAS6 and its receptor MERTK in rheumatoid arthritis. Multi-omics integrated analysis of synovial tissue and peripheral blood mononuclear cells of RA patients reveals common dysregulation of transcriptomics and epitranscriptomics, highlighting genes with both differential expression and m6A modification, which are enriched in processes such as phagocytosis, Th17 differentiation and cell aging. Among these genes, GAS6 shows the most significant m6A hypermethylation and expression up-regulation, and is verified as a key effector molecule interacting with MERTK / AXL receptor. Functional experiments show that GAS6 and MERTK synergistically promote the malignant phenotype of RA fibroblast-like synoviocytes, enhance their proliferation, migration, inflammatory cytokine secretion and anti-apoptotic ability.

The utility model aims to provide an anti-blocking filter for aseptically collecting synovial tissues in arthroscopic surgery, and relates to the technical field of medical instruments, an upper cover cylinder is detachably connected with a lower filter cylinder, a funnel-shaped filter screen is fixedly arranged in the lower filter cylinder, an anti-blocking cylinder is arranged at the bottom of the filter screen in a sliding manner, and the anti-blocking cylinder is fixedly connected with the upper cover cylinder. A plurality of through holes are formed in the outer wall and the bottom of the anti-blocking cylinder; a strong magnet is arranged in the top of the anti-blocking cylinder; a controller in an upper cover cylinder discontinuously controls a power supply to output current forwards and backwards to an electromagnet, so that the electromagnet attracts or repels a strong magnet in an anti-blocking cylinder, the anti-blocking cylinder is controlled to slide up and down on a limiting column, and a sliding film gathered at the bottom of a filter screen can be ejected upwards; the liquid can flow into the liquid outlet pipe through the through holes in the outer wall and the bottom of the anti-blocking cylinder, so that a large amount of liquid is prevented from remaining on the filter screen; the contact with the filter screen can be avoided through a detachable connection mode, and the sliding film at the bottom of the filter screen can be taken out through tweezers.

The invention provides an extract with an acute gouty arthritis relieving effect and application thereof. The medicine is used for treating acute gouty arthritis of mammals. The plantain extract acts on an acute gouty arthritis model rat in a specific intragastric administration mode, the joint swelling degree of the model rat can be remarkably reduced, and inflammatory cell infiltration of synovial tissue is relieved.

This invention belongs to the field of traditional Chinese medicine preparation technology, and provides a traditional Chinese medicine composition with anti-inflammatory, swelling-reducing, analgesic, and joint-relieving properties, its preparation method, and its application in the preparation of drugs for treating arthralgia. The method includes the following steps: Smilax glabra, Corydalis yanhusuo (processed with vinegar), and Stephania tetrandra are pulverized, mixed, decocted with water, filtered, the filtrate is concentrated, ethanol is added to precipitate, the supernatant is collected, the ethanol is recovered and concentrated to obtain a water-extracted alcohol-immersed extract, which is then mixed with maltodextrin, wet-granulated, and dried to obtain the traditional Chinese medicine composition. The traditional Chinese medicine composition obtained by this invention is based on the principles of promoting joint mobility, reducing swelling and relieving pain. It can significantly inhibit ankle joint swelling in rats with gouty arthritis, improve local inflammatory cell infiltration, and reduce synovial tissue hyperplasia in rats with gouty arthritis.

The invention belongs to the technical field of biological medicines, and particularly relates to application of mesenchymal stem cells combined with methotrexate in preparation of an anti-RA medicine. The mesenchymal stem cells are human umbilical cord mesenchymal stem cells; the human umbilical cord mesenchymal stem cells highly express CD73, CD90 and CD105, and low express CD34, CD45 and HLA-DR (Human Leukocyte Antigen-DR). The research proves that the human umbilical cord mesenchymal stem cells and methotrexate have better treatment effect compared with single human umbilical cord mesenchymal stem cells or methotrexate when being used for treating rheumatoid arthritis by combining with the human umbilical cord mesenchymal stem cells or methotrexate. RA inflammation can be effectively relieved, synovial tissue cell apoptosis can be inhibited, synovial macrophage polarization can be adjusted by regulating related signal channels, and then RA can be effectively treated.

The invention provides a PAD4 inhibitor and synovial membrane targeting peptide conjugate as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The PAD4 inhibitor and synovial membrane targeting peptide conjugate provided by the invention has a synovial membrane targeting peptide structure, and can enter and be accumulated in joint tissues through systemic circulation after administration. The linker used in the invention has a chemical bond which can be split under an acidic or oxidation condition, and can quickly release ZT-5 in a responsive manner under low pH and high oxidation conditions in an arthritis inflammation microenvironment, so that the effect of resisting rheumatoid arthritis is achieved. Meanwhile, the ZT-5 can be enriched into the facet joint cavity by utilizing the excessively proliferated synovial tissue, so that the bioavailability of the ZT-5 is improved, the administration frequency is reduced, and the defect of poor pharmacokinetic performance of a PAD4 inhibitor based on a Cl-amidine structure is overcome.

The invention provides an application of a secreting type curl-related protein in preparation of a medicine for treating arthritis and the medicine for treating the arthritis, and belongs to the technical field of biology. According to the present invention, the research results show that the secreting type curling-related protein has good arthritis treatment effect, can significantly up-regulate the expression level of the II type collagen marker COL2A1 and the SOX family transcription factor SOX5 in the damaged cartilage cells, and can promote the expression of the cell cycle-related protein Ki67 to achieve the enhancement of the cartilage cell proliferation ability. Meanwhile, the SFRP can regulate the polarization phenotype of human synovial macrophages in a targeted manner and remarkably inhibit expression of a proinflammatory M1 macrophage marker iNOS, so that release of inflammatory factors in a synovial tissue inflammatory microenvironment is reduced, synovial inflammation is regulated in a targeted manner, and arthralgia is remarkably relieved.

The invention discloses a paeoniflorin-loaded plant nano-vesicle and an application of the paeoniflorin-loaded plant nano-vesicle in preparation of a medicine for regulating rheumatoid arthritis. According to the plant nano-vesicle, the gardenia source exosome serves as a carrier, paeoniflorin is loaded through an ultrasonic method, cyclopeptide RGD and CD47 mimic peptide are modified on the surface, the plant nano-vesicle can be prevented from being cleared away by macrophages, and the plant nano-vesicle can penetrate through a synovial vessel barrier and a compact extracellular matrix and is accurately delivered to inflammatory synovial tissue, so that the effect of preventing inflammation is achieved. According to the delivery system, the stability and bioavailability of paeoniflorin are effectively improved, MALAT1 related signal channels can be down-regulated, ERK / MAPK abnormal activation is inhibited, expression of inflammatory factors such as IL-2, IL-6 and TNF-alpha is remarkably reduced, and rheumatoid arthritis synovial inflammation is relieved; the invention has the advantages of high targeting property, long circulation, low immunogenicity and multi-dosage form adaptability, provides a safe and efficient novel delivery strategy for traditional Chinese medicine active ingredients, and has a wide application prospect.

This invention discloses a method, targets, and applications for the diagnosis and treatment of hemophilic arthritis. The method includes: obtaining cartilage and synovial membrane samples from patients with hemophilic arthritis undergoing total knee arthroplasty; performing single-cell RNA sequencing, single-cell ATAC sequencing, and spatial transcriptomics analysis to determine the main cell types and key cell subpopulations constituting the microenvironment of hemophilic arthritis; identifying the molecular characteristics and differentiation processes of chondrocyte and synovial fibroblast subpopulations; measuring intercellular interactions in the knee joint microenvironment of the samples; and identifying specific regulatory transcription factors in hemophilic arthritis through paired epigenetic analysis to identify diagnostic and therapeutic targets for hemophilic arthritis. This method integrates single-cell multi-omics analysis to analyze the cellular characteristics of synovial and cartilage tissues and their interactions in the epigenetic pathogenic mechanism, identifying potential therapeutic targets.